Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics and pharmacodynamics - PubMed (original) (raw)
Clinical Trial
Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics and pharmacodynamics
N R Cutler et al. Clin Pharmacol Ther. 1995 Jul.
Abstract
Objective: To determine the pharmacokinetics, pharmacodynamics and safety of the acetylcholinesterase inhibitor zifrosilone in healthy male volunteers.
Methods: Pharmacokinetics, pharmacodynamics, and tolerance of zifrosilone were studied in a double-blind, sequential, single-escalating-dose, randomized panel design. Each panel consisted of six subjects, with four subjects receiving zifrosilone (10, 30, 60, 90, 120, 150, 200, 250, and 300 mg orally) and two subjects receiving matching placebo. Serial blood samples were obtained for zifrosilone plasma concentrations and red blood cell acetylcholinesterase and butyrylcholinesterase activities. Participating subjects (n = 54) were men between the ages of 18 and 45 years. Each subject had a normal physical examination, electrocardiogram, serum chemistries, hematology, urinalysis, and test for human immunodeficiency virus at screening.
Results: A greater than proportionate increase in mean plasma concentration values for area under the curve from time zero to infinity was observed over the 200 to 300 mg dose range groups. Red blood cell acetylcholinesterase showed a dose-inhibition relationship, with a mean maximum inhibition of 20.9% at 10 mg that increased to 62.1% at 300 mg. Butyrylcholinesterase activity was relatively unaffected by zifrosilone (< 20% inhibition at 300 mg). For doses > or = 200 mg, an Emax pharmacodynamic model was used to describe the relationship between zifrosilone plasma concentration and red blood cell acetylcholinesterase inhibition (Emax = 83.8%; EC50 = 0.65 ng/ml).
Conclusions: Zifrosilone showed dose-dependent pharmacokinetics after oral administration and was effective in causing selective inhibition of red blood cell acetylcholinesterase.
Similar articles
- Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery.
Dow J, Dulery BD, Hornsperger JM, Di Francesco GF, Keshary P, Haegele KD. Dow J, et al. Arzneimittelforschung. 1995 Dec;45(12):1245-52. Arzneimittelforschung. 1995. PMID: 8595078 - Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA. Bergman AJ, et al. Clin Ther. 2006 Jan;28(1):55-72. doi: 10.1016/j.clinthera.2006.01.015. Clin Ther. 2006. PMID: 16490580 Clinical Trial. - Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Christopher R, Covington P, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A. Christopher R, et al. Clin Ther. 2008 Mar;30(3):513-27. doi: 10.1016/j.clinthera.2008.03.005. Clin Ther. 2008. PMID: 18405789 Clinical Trial. - Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM, van Vliet A, Abou Farha K, Cherrington JM, Campbell DA, Li X, Hanway D, Li J, Guler HP. O'Farrell AM, et al. Clin Ther. 2007 Aug;29(8):1692-705. doi: 10.1016/j.clinthera.2007.08.005. Clin Ther. 2007. PMID: 17919550 Clinical Trial. - Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, Wang AQ, Zeng W, Musson D, Winchell G, Davies MJ, Ramael S, Gottesdiener KM, Wagner JA. Herman GA, et al. Clin Pharmacol Ther. 2005 Dec;78(6):675-88. doi: 10.1016/j.clpt.2005.09.002. Clin Pharmacol Ther. 2005. PMID: 16338283 Clinical Trial.
Cited by
- Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?
Becker RE, Greig NH, Giacobini E. Becker RE, et al. J Alzheimers Dis. 2008 Oct;15(2):303-25. doi: 10.3233/jad-2008-15213. J Alzheimers Dis. 2008. PMID: 18953116 Free PMC article. Review. - 1-(3-_Tert_-Butylphenyl)-2,2,2-Trifluoroethanone as a Potent Transition-State Analogue Slow-Binding Inhibitor of Human Acetylcholinesterase: Kinetic, MD and QM/MM Studies.
Zueva IV, Lushchekina SV, Pottie IR, Darvesh S, Masson P. Zueva IV, et al. Biomolecules. 2020 Nov 27;10(12):1608. doi: 10.3390/biom10121608. Biomolecules. 2020. PMID: 33260981 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources